You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

464 Results
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
New Drug Funding Program
    Teclistamab (Outpatient) - Relapsed or Refractory Multiple Myeloma
High Cost Therapy Funding Program
    Teclistamab (Inpatient) - Relapsed or Refractory Multiple Myeloma
Jul 2025
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Adjuvant, Curative
Funding:
ODB - General Benefit
    abiraterone
ODB - General Benefit
    prednisone
Jul 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Jul 2025
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Intent: Palliative
Jul 2025
Regimen
Intent: Adjuvant, Curative, Palliative
Jul 2025
Drug
Other Name(s): Herceptin® , Kanjinti™; Ogivri™; Trazimera™; Herzuma®; Ontruzant®
Dec 2024
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Myeloid (CML)
Intent: Palliative
Funding:
Exceptional Access Program
    asciminib - For the treatment of Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase, based on criteria
Jul 2025
Drug
Other Name(s): Tecvayli®
Jul 2025
Drug
Other Name(s): Temodal®
Aug 2025

Pages